Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.

The conversation discusses finding a finasteride dosage that reduces DHT by about 25% to minimize side effects, with considerations for topical versus oral formulations. Alternatives like dutasteride mesotherapy and topical treatments are explored, with concerns about systemic absorption and potential impacts on athletic performance and hormone levels.

Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.

A 20-year-old is considering using topical spironolactone for hair loss after experiencing side effects from finasteride. Another user shares their regimen, which includes dutasteride, spironolactone, cetirizine, and minoxidil, while caution is advised against spironolactone due to potential systemic effects.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

RU58841 is discussed as a hair loss treatment, with concerns about potential heart risks and systemic side effects. Some users suggest trying FDA-approved treatments like finasteride first, while others debate the safety and cost-effectiveness of RU58841.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.

Topical finasteride reduces scalp DHT, with some going systemic. Using 0.025% at 1ml per day can stabilize hair loss without side effects.

Applying minoxidil immediately after microneedling at 0.5mm can cause stinging and potential systemic absorption, so some users prefer to wait 12-24 hours. Others report no issues with immediate application, but caution is advised to avoid irritation and side effects.

Topical dutasteride, especially at higher concentrations, can be effective for hair loss when combined with microneedling to enhance absorption. Users discuss the side effects of finasteride and dutasteride, with some preferring topical treatments to avoid systemic side effects.

The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

The user transitioned from finasteride to RU58841 and oral minoxidil to maintain hair gains while avoiding systemic DHT suppression. They have not experienced increased shedding or side effects since stopping finasteride and hope RU58841 will preserve their hair.

A user reported positive results using finasteride 1.25mg daily for six years with no side effects, highlighting early treatment benefits. Others discussed experiences with finasteride, minoxidil, and dutasteride, mentioning different side effects and effectiveness.

Caffeine may promote hair growth and potentially inhibit 5-α-reductase activity in hair follicles, but its effectiveness and systemic impact remain unclear. Users discuss using topical caffeine solutions, with some experiencing no side effects compared to finasteride.

The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.

There is skepticism about new hair loss treatments, with the belief that current options like minoxidil, finasteride, and hair transplants are the best available. Concerns are raised about the systemic side effects of androgen-related treatments, even those marketed as topical, and doubts about the effectiveness of emerging treatments like clascoterone.

Clascoterone, a topical anti-androgen, shows promise for treating female pattern hair loss without systemic side effects, offering a potential alternative to minoxidil. It could also benefit men who experience side effects from finasteride.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The conversation discusses using a 0.03% topical Dutasteride solution for hair loss, as it may be more effective than Finasteride with fewer systemic side effects. OP plans to apply it daily for 100 days, then reduce frequency, due to past negative cognitive effects from oral treatments.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Finasteride can increase body and facial hair growth due to increased testosterone, despite its intended use to reduce hair loss on the scalp. Some users consider trying topical finasteride for less systemic impact, while others report mixed results and side effects.

Dutasteride mesotherapy is discussed as a potential treatment for hair loss, with some users suggesting it offers a slight boost when combined with oral minoxidil, though it's costly. Concerns about side effects and systemic absorption are noted, with alternatives like topical dutasteride and microneedling suggested for home use.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.